Page last updated: 2024-08-25

zoledronic acid and Complications of Diabetes Mellitus

zoledronic acid has been researched along with Complications of Diabetes Mellitus in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N1
Kajizono, M; Kitamura, Y; Matsuoka, J; Sada, H; Sendo, T; Soga, Y; Sugiura, Y1
Arnol, V; Cortizo, AM; Felice, JI; Gangoiti, MV; McCarthy, AD1

Other Studies

3 other study(ies) available for zoledronic acid and Complications of Diabetes Mellitus

ArticleYear
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
    The Bulletin of Tokyo Dental College, 2013, Volume: 54, Issue:2

    Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Arthritis, Rheumatoid; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diabetes Complications; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Parenteral; Japan; Male; Middle Aged; Oral Surgical Procedures; Osteoporosis; Prostatic Neoplasms; Risedronic Acid; Treatment Outcome; Wound Healing; Zoledronic Acid

2013
Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
    Biological & pharmaceutical bulletin, 2015, Volume: 38, Issue:12

    Topics: Aged; Anemia; Bone Density Conservation Agents; Bone Diseases; Denosumab; Dental Care; Diabetes Complications; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw; Logistic Models; Male; Middle Aged; Neoplasms; Odds Ratio; Osteonecrosis; Retrospective Studies; Risk Factors; Zoledronic Acid

2015
Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells.
    European journal of pharmacology, 2008, Dec-14, Volume: 600, Issue:1-3

    Topics: 3T3 Cells; Alendronate; Animals; Bone Density Conservation Agents; Calcium; Calcium Channels, L-Type; Cattle; Cell Line; Diabetes Complications; Diphosphonates; Dose-Response Relationship, Drug; Glycation End Products, Advanced; Imidazoles; Mice; Osteoblasts; Osteoporosis; Pamidronate; Rats; Reactive Oxygen Species; Serum Albumin, Bovine; Time Factors; Zoledronic Acid

2008